Jaguar Health (JAGX) Cash & Equivalents (2014 - 2026)

Jaguar Health (JAGX) has 13 years of Cash & Equivalents data on file, last reported at $7.3 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $7.3 million, up 27.91% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 27.91% YoY), and the FY2025 annual result was $968000.0, down 87.9% from the prior year.
• Cash & Equivalents advanced to $7.3 million in Q1 2026 per JAGX's latest filing, from $968000.0 in the prior quarter.
• Over five years, Cash & Equivalents peaked at $17.5 million in Q1 2022 and troughed at $968000.0 in Q4 2025.
• A 5-year average of $8.5 million and a median of $8.0 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents jumped 311.31% in 2024, then sank 87.9% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $5.5 million in 2022, then gained by 18.28% to $6.5 million in 2023, then increased by 23.7% to $8.0 million in 2024, then slumped by 87.9% to $968000.0 in 2025, then soared by 651.86% to $7.3 million in 2026.
• Business Quant data shows JAGX's Cash & Equivalents at $7.3 million in Q1 2026, $968000.0 in Q4 2025, and $3.5 million in Q3 2025.